FAQ
Drugs

【Clinical】Regarding Article 38-2 of the Regulations for Registration of Medicinal Products, how to defined the “valid Taiwanese subjects” in a clinical trial to fulfill the requirement?

刊登日期:2019-11-11  |  點閱次數 : 406 次 

Article 38-2 of the Regulations for Registration of Medicinal Products specify the number of Taiwanese subjects that can be assessed "in principle". It will also be adjusted on a case-by-case consideration.

 

(中文版)


上一筆 Which nonclinical Pharm/Tox study data need to be provided for marketing authoriz
下一筆 【Clinical】What are the points for consideration when reviewing new drug applica